Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | EGFR | P00533 | 3/20 | 0.52 |
| ▸ | JAK3 | P52333 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 3/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | ITK | Q08881 | 1/20 | 0.51 |
| ▸ | CTSC | P53634 | 3/20 | 0.51 |
| ▸ | SYK | P43405 | 3/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.48 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL270594 | 0.91 | CTSC (0.58) | CTSCSYK | |
| SCHEMBL17916004 | 0.90 | KDR (0.61) | BTKMEN1KMT2AEGFRJAK3 | |
| SCHEMBL270226 | 0.89 | EGFR (0.62) | BTKEGFRJAK3ITKSYK | |
| SCHEMBL271089 | 0.88 | EGFR (0.66) | BTKKMT2AEGFRJAK3ITK | |
| SCHEMBL12320591 | 0.87 | EGFR (0.56) | BTKMEN1KMT2AEGFRJAK3 | |
| SCHEMBL270239 | 0.84 | EGFR (0.58) | BTKEGFRJAK3ITKSYK | |
| SCHEMBL270241 | 0.81 | BRD4 (0.61) | BTKEGFRJAK3ITKCTSC | |
| SCHEMBL265644 | 0.80 | BRD4 (0.75) | JAK3LCKKDRCTSCMAPK14 | |
| SCHEMBL17915942 | 0.79 | IDH2 (0.64) | EGFRJAK3LCKKDRCTSC | |
| SCHEMBL14536376 | 0.79 | BRD4 (0.62) | EGFRJAK3LCKKDRCTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-8133900-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| US-7825246-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| WO-2010017122-A2 | METHODS OF TREATING THALASSEMIA | TARGEGEN INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | TARGEGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
| WO-2007053452-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286789-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, LTK | BTK 7/4885MEN1 4175/4885KMT2A 1279/4885 |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | BTK 9/4885MEN1 4047/4885KMT2A 1296/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | BTK 9/4885MEN1 4047/4885KMT2A 1296/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | BTK 9/4885MEN1 4047/4885KMT2A 1296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.